Ketoprofen additional labeling for G-I problems, elderly deemed unnecessary.
This article was originally published in The Tan Sheet
Executive Summary
KETOPROFEN ADDITIONAL LABELING FOR G-I PROBLEMS DEEMED UNNECESSARY by FDA's Nonprescription Drugs and Arthritis Advisory Committees at a July 14 joint meeting. Following a discussion of whether ketoprofen should bear warnings on potential gastrointestinal problems, the advisory committees agreed unanimously that standard labeling for the analgesic class of drugs sufficiently addresses potential problems associated with ketoprofen in both the general population and the elderly. The committees recommended ketoprofen for approval as an over-the-counter analgesic ("The Tan Sheet" July 17, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning